Benjamin Corcoran
YOU?
Author Swipe
View article: Musculoskeletal pain in Parkinson's disease: Association with dopaminergic deficiency in the caudate nucleus
Musculoskeletal pain in Parkinson's disease: Association with dopaminergic deficiency in the caudate nucleus Open
Background Musculoskeletal (MSK) pain affects over 80% of People with Parkinson's (PD, PwP) and may, in part, be dopaminergic in origin, as dopaminergic medication often leads to its relief. Methods PwP who underwent striatal dopamine tran…
View article: Metastatic malignancy mimics: a rare case of traumatic splenosis mimicking intra-abdominal malignancy
Metastatic malignancy mimics: a rare case of traumatic splenosis mimicking intra-abdominal malignancy Open
We present a case of a patient, undergoing imaging for an unrelated presentation, whose adolescent abdominal trauma had caused an unrecognised disseminated intra-abdominal splenosis, resulting in an imaging presentation on CT that suggeste…
View article: Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study
Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study Open
View article: Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours Open
View article: Application of Normative Occipital Condyle-C1 Interval Measurements to Detect Atlanto-Occipital Injury in Children
Application of Normative Occipital Condyle-C1 Interval Measurements to Detect Atlanto-Occipital Injury in Children Open
Occipital condyle-C1 interval widening cutoffs used to establish atlanto-occipital injury lack both sensitivity and specificity in children and young teenagers. MR imaging is necessary to establish a diagnosis of atlanto-occipital injury i…
View article: <sup>177</sup>Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis—dosimetric considerations
<sup>177</sup>Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis—dosimetric considerations Open
We report on a case of a 68-year-old female, currently a dialysis-dependant patient with disseminated metastatic neuroendocrine tumour, treated with 177Lu-Dotatate. As 177Lu-Dotatate is cleared predominantly by the ki…